Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica, a biopharmaceutical company, has announced that Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, has received approval from the Finland's National Agency for Medicines.
Subscribe to our email newsletter
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino received national regulatory approval in Finland.
Following the regulatory approval of Toctino in Finland, Basilea will submit a pricing and reimbursement dossier to the Finnish authorities.
Toctino (alitretinoin) was developed by Basilea Pharmaceutica International.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.